Indeed, acute and chronic kidney damage have been described in patients receiving PRRT and in animal models [ 2– 5] and kidney toxicity is currently dose-limiting in PRRT [ 3, 4, 6].
As a consequence, currently used dosing regimens may not assure optimal efficacy or minimal toxicity in these patients.
The compound is currently being dosed in cancer patients, to evaluate its potential applicability in a broad spectrum of human malignancies.
Based on these findings, the currently used colistin dosing regimens might not provide the most effective therapy and therefore might justify administering larger colistin doses in longer intervals.
This is insufficiently anticipated by currently recommended dosing guidelines.
Like the single-agent pazopanib dose-finding study, the tolerable dose is higher than the currently approved dose, chosen on the basis of PK parameters and analyses of biological activity (Hurwitz et al, 2009).
We found in this study that at the currently used doses, febuxostat (most common dose of 40 mg/day) was more effective in achieving the target sUA than allopurinol (most common doses of 300 mg/day or lower).
However, in these studies, only a small numbers of patients were included and the weight-based GH dose was higher than the currently used dose aimed at normalizing IGF-I.
Data from a trial evaluating the concurrent combination of ipilimumab and vemurafenib at their currently approved doses, or with a lower dose of vemurafenib, in patients with metastatic melanoma resulted in greater hepatotoxicity than expected for either agent alone 42.
The dose of temsirolimus was based on its currently approved dose for the treatment of renal cancer.
